Ghent University Academic Bibliography

Advanced

BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis

Wouter Willaert, Kurt Van Der Speeten, Gabriel Liberale and Wim Ceelen UGent (2015) BMC CANCER. 15.
abstract
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However, even after optimal cytoreduction, systemic and locoregional recurrence are common. Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients. Methods/Design: The BEV-IP study is a phase II, single-arm, open-label study aimed at patients with colorectal or appendiceal adenocarcinoma with synchronous or metachronous PC. This study evaluates whether perioperative chemotherapy including BEV in combination with CRS and oxaliplatin-based IPC results in acceptable morbidity and mortality (primary composite endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related toxicity, pathological response, progression free survival, and overall survival. Discussion: The BEV-IP trial is the first prospective assessment of the safety and efficacy of perioperative chemotherapy combined with anti-angiogenic treatment in patients undergoing CRS and IPC for colorectal peritoneal metastases.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
RANDOMIZED-TRIAL, PLUS BEVACIZUMAB, LIVER METASTASES, MALIGNANT ASCITES, SYSTEMIC CHEMOTHERAPY, NEOADJUVANT CHEMOTHERAPY, PERITONEAL CARCINOMATOSIS, INTERSTITIAL FLUID PRESSURE, Peritoneal carcinomatosis, Perioperative chemotherapy, HIPEC, OVARIAN-CANCER, SURGERY, Cytoreductive surgery, Bevacizumab, Colorectal cancer
journal title
BMC CANCER
BMC Cancer
volume
15
article number
980
pages
8 pages
Web of Science type
Article
Web of Science id
000366545900036
JCR category
ONCOLOGY
JCR impact factor
3.265 (2015)
JCR rank
85/213 (2015)
JCR quartile
2 (2015)
ISSN
1471-2407
DOI
10.1186/s12885-015-1954-x
language
English
UGent publication?
yes
classification
A1
copyright statement
I have retained and own the full copyright for this publication
id
7036724
handle
http://hdl.handle.net/1854/LU-7036724
date created
2016-01-13 15:24:20
date last changed
2016-12-21 15:41:53
@article{7036724,
  abstract     = {Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However, even after optimal cytoreduction, systemic and locoregional recurrence are common. Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients. 
Methods/Design: The BEV-IP study is a phase II, single-arm, open-label study aimed at patients with colorectal or appendiceal adenocarcinoma with synchronous or metachronous PC. This study evaluates whether perioperative chemotherapy including BEV in combination with CRS and oxaliplatin-based IPC results in acceptable morbidity and mortality (primary composite endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related toxicity, pathological response, progression free survival, and overall survival. 
Discussion: The BEV-IP trial is the first prospective assessment of the safety and efficacy of perioperative chemotherapy combined with anti-angiogenic treatment in patients undergoing CRS and IPC for colorectal peritoneal metastases.},
  articleno    = {980},
  author       = {Willaert, Wouter and Van Der Speeten, Kurt and Liberale, Gabriel and Ceelen, Wim},
  issn         = {1471-2407},
  journal      = {BMC CANCER},
  keyword      = {RANDOMIZED-TRIAL,PLUS BEVACIZUMAB,LIVER METASTASES,MALIGNANT ASCITES,SYSTEMIC CHEMOTHERAPY,NEOADJUVANT CHEMOTHERAPY,PERITONEAL CARCINOMATOSIS,INTERSTITIAL FLUID PRESSURE,Peritoneal carcinomatosis,Perioperative chemotherapy,HIPEC,OVARIAN-CANCER,SURGERY,Cytoreductive surgery,Bevacizumab,Colorectal cancer},
  language     = {eng},
  pages        = {8},
  title        = {BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis},
  url          = {http://dx.doi.org/10.1186/s12885-015-1954-x},
  volume       = {15},
  year         = {2015},
}

Chicago
WILLAERT, WOUTER, Kurt Van Der Speeten, Gabriel Liberale, and Wim Ceelen. 2015. “BEV-IP: Perioperative Chemotherapy with Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis.” Bmc Cancer 15.
APA
WILLAERT, W., Van Der Speeten, K., Liberale, G., & Ceelen, W. (2015). BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis. BMC CANCER, 15.
Vancouver
1.
WILLAERT W, Van Der Speeten K, Liberale G, Ceelen W. BEV-IP: perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis. BMC CANCER. 2015;15.
MLA
WILLAERT, WOUTER, Kurt Van Der Speeten, Gabriel Liberale, et al. “BEV-IP: Perioperative Chemotherapy with Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis.” BMC CANCER 15 (2015): n. pag. Print.